Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. ConvaTec Group Plc
  6. News
  7. Summary
    CTEC   GB00BD3VFW73

CONVATEC GROUP PLC

(CTEC)
  Report
Delayed London Stock Exchange  -  11:35 2022-10-05 am EDT
208.20 GBX   -0.57%
09/19ConvaTec Group Plc(LSE:CTEC) dropped from FTSE 250 Index
CI
09/19ConvaTec Group Plc(LSE:CTEC) dropped from FTSE 250 (Ex Investment Companies) Index
CI
09/19ConvaTec Group Plc(LSE:CTEC) added to FTSE 100 Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Former Non-Executive Chairman Of UK-Listed Company Fined For Unlawfully Disclosing Inside Information As A Result Of Negligence

08/12/2022 | 04:10pm EDT

Christopher Gent, a former CEO of Vodafone Group plc and non-executive Chairman of GlaxoSmithKline plc, was appointed as the non-executive Chairman of ConvaTec Group Plc ("ConvaTec"), a company admitted to trading on the London Stock Exchange ("LSE"), in October 2016 and held this position until retirement in May 2019. In his role, Mr. Gent was responsible for governance over, and closely involved in the preparation of, ConvaTec's issuance of key company news ("RNS") announcements to the LSE. In October 2018, Mr. Gent previewed the release of an expected RNS announcement relating to the downward revision of ConvaTec's financial guidance and the retirement of ConvaTec's CEO before such information had been announced to the market. The disclosures were made to two individuals in senior positions at two of ConvaTec's major shareholders under the belief that it was in the best interests of ConvaTec that these investors received the information ahead of the public announcement (which was made five days after the private communications). The UK Financial Conduct Authority ("FCA") determined that Mr. Gent's actions amounted to an unlawful disclosure of inside information and that he therefore committed market abuse in breach of the UK Market Abuse Regulation ("MAR"). He was fined Ł80,000.

The factors relevant to the FCA's assessment over the conduct at issue were that Mr. Gent was an experienced industry professional and held a senior position within his organization. In concluding that the market abuse was committed negligently, the FCA maintained that "[h]aving received relevant training on MAR from ConvaTec's external legal advisers [...], and based on his own considerable experience and position, Sir Christopher should have realised that the information he disclosed amounted, or may have amounted, to inside information and that it was not in the normal exercise of his employment, profession or duties selectively to disclose it. Sir Christopher failed properly to apply his mind to the specific question of what information, if any, he might properly disclose, as well as when, in what manner and to whom, and he failed to obtain clear, formal advice regarding this question, before making the disclosures." The FCA acknowledged and accepted Mr. Gent's explanation that he believed that he was acting in the best interests of ConvaTec in his role as its Chairman by making the disclosures, yet this could not excuse his actions because the FCA resolved that his conduct undermined investor confidence in the integrity of financial markets.

The FCA final notice (issued on August 5, 2022) is available here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mr Michael Sholem
Cadwalader, Wickersham & Taft LLP
200 Liberty Street New York
New York
NY 10281
UNITED STATES
Tel: 2125046000
Fax: 2125046666
E-mail: cwtinfo@cwt.com
URL: www.cadwalader.com

© Mondaq Ltd, 2022 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about CONVATEC GROUP PLC
09/19ConvaTec Group Plc(LSE:CTEC) dropped from FTSE 250 Index
CI
09/19ConvaTec Group Plc(LSE:CTEC) dropped from FTSE 250 (Ex Investment..
CI
09/19ConvaTec Group Plc(LSE:CTEC) added to FTSE 100 Index
CI
09/13‘Sir, You Have Committed Market Abuse'
AQ
09/12Recent FCA And English High Court Decisions Provide Guidance On Unlawful Disclosure Of ..
AQ
09/08Dear Ceos : Market Abuse, Conflicts Of Interest And ESG At The Forefront Of The FCA's Supe..
AQ
09/07EMEA Morning Briefing: Fears Over Hawkish Fed, Europe's Energy Cri..
DJ
08/31Abrdn, Hikma, Howden Joinery to Exit FTSE 100; ConvaTec, Others Take Spots
MT
08/30Who's up, who's down
AQ
08/23Abrdn, Hikma Pharmaceuticals Likely To Leave FTSE 100 Index
MT
More news
Analyst Recommendations on CONVATEC GROUP PLC
More recommendations
Financials (USD)
Sales 2022 2 068 M - -
Net income 2022 93,1 M - -
Net Debt 2022 979 M - -
P/E ratio 2022 48,1x
Yield 2022 2,43%
Capitalization 4 780 M 4 780 M -
EV / Sales 2022 2,79x
EV / Sales 2023 2,64x
Nbr of Employees 10 000
Free-Float 80,2%
Chart CONVATEC GROUP PLC
Duration : Period :
ConvaTec Group Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CONVATEC GROUP PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 2,34 $
Average target price 3,13 $
Spread / Average Target 33,5%
EPS Revisions
Managers and Directors
Karim Sani Nasib Bitar Chief Executive Officer & Director
Jonathan Peter Mason Chief Financial Officer & Director
John David Gibson McAdam Chairman
Robert Steele EVP-Quality, Clinical & Regulatory Affairs
Divakar Ramakrishnan Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
CONVATEC GROUP PLC8.41%4 888
ABBOTT LABORATORIES-26.76%180 516
MEDTRONIC PLC-18.32%112 313
BECTON, DICKINSON AND COMPANY-3.58%67 583
HOYA CORPORATION-14.49%36 225
DEXCOM, INC.-32.23%35 713